InflaRx registers up to $65 million in ordinary shares for at-the-market salesAug 14FinancingInflaRx N.V.
Amgen updates MariTide pipeline, discontinues AMG 513, keeps pressing FDA on TAVNEOSAug 4Quarterly updateAMG-513Amgen
InflaRx weighs broader EU strategy for vasculitis drugs after Tavneos setbackJun 30Regulatory decisionavacopanInflaRx N.V.
Sign inSign in